8-K: Ginkgo Bioworks Reports 61% Revenue Increase in Q3 2024, Driven by Non-Cash Item, While Restructuring Efforts Continue

Ginkgo Bioworks saw a 61% increase in total revenue in Q3 2024, primarily due to a one-time non-cash revenue release, while also making progress on cost reductions and strategic partnerships.

Summary

• Ginkgo Bioworks reported a total revenue of $89 million for the third quarter of 2024, a 61% increase compared to the same period last year.
• This increase was largely due to a $45 million non-cash revenue release from a terminated customer agreement.
• Excluding this one-time item, total revenue was $44 million, a 21% decrease year-over-year.
• Cell Engineering revenue was $30 million, down 20% year-over-year, due to a shift towards larger customers and restructuring changes.
• Biosecurity revenue was $14 million with a 28% gross profit margin, a decrease from the prior year due to the expected reduction in K-12 testing.
• The company reported a loss from operations of $(55) million, an improvement from $(286) million in the same quarter last year.
• Adjusted EBITDA was $(20) million, up from $(84) million in the prior year period, also benefiting from the non-cash revenue release.
• Ginkgo's cash and cash equivalents balance stood at $616 million at the end of the third quarter.
• The company is accelerating site consolidation and cost reduction initiatives, aiming for Adjusted EBITDA breakeven by the end of 2026.
• A reduction in force is expected to achieve over $85 million in annualized savings by mid-2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments like revenue growth (due to a non-cash item), new partnerships, and cost-cutting measures, the underlying revenue decline and continued losses temper the overall sentiment. The restructuring also introduces uncertainty.

Positives

• Ginkgo's total revenue increased significantly due to a non-cash revenue release.
• The company made progress in reducing its operating loss and improving Adjusted EBITDA.
• Ginkgo secured new and expanded partnerships with major companies like Novo Nordisk and Merck.
• The company is actively working on cost reduction measures, including a reduction in force and site consolidation.
• Ginkgo is making progress towards its goal of achieving Adjusted EBITDA breakeven by the end of 2026.
• The company added 25 new programs and other customer contracts to the Cell Engineering platform.
• Ginkgo validated its approach to rapidly detect H5N1 and has updated its offerings to include DNA sequencing of raw milk, bioinformatics as a service and comprehensive analyzed data sets.

Negatives

• Excluding the non-cash revenue release, total revenue decreased by 21% year-over-year.
• Cell Engineering revenue decreased by 20% year-over-year.
• Biosecurity revenue decreased due to the expected ramp down of K-12 testing.
• The company continues to operate at a loss, although the loss has decreased compared to the previous year.
• The company is undergoing a restructuring process, which may cause uncertainty.

Risks

• The company's ability to realize cost savings from site consolidation and the reduction in force is not guaranteed.
• There is volatility in the price of Ginkgo's securities due to various factors.
• The company faces risks related to the demand for synthetic biology products and biosecurity services.
• There is uncertainty regarding the success of the company's Foundry platform programs and the product development of its customers.
• The company is subject to legal proceedings and regulatory risks.
• The company's ability to achieve Adjusted EBITDA breakeven by the end of 2026 is not guaranteed.

Future Outlook

Ginkgo updated its full-year 2024 revenue guidance to $215-235 million, reflecting the $45 million non-cash revenue release. The company aims to achieve Adjusted EBITDA breakeven by the end of 2026.

Management Comments

• Jason Kelly, co-founder and CEO of Ginkgo, stated that he is extremely proud of the significant progress made in the third quarter.
• Jason Kelly mentioned that the team has been laser-focused on delivering for customers while driving down costs even further.
• Jason Kelly noted that the company is achieving ambitious milestones, signing new deals, and launching new offerings.
• Jason Kelly highlighted the substantial consolidation of the company's real estate footprint by exiting several facilities.
• Jason Kelly expressed gratitude to Arie Belldegrun for his service and welcomed Sri Kosuri to the board.

Industry Context

Ginkgo's focus on cell programming and biosecurity aligns with growing trends in biotechnology and the increasing need for advanced biological solutions. The company's partnerships with major pharmaceutical and tech companies indicate its relevance in the industry. The restructuring and cost-cutting measures reflect a broader trend in the biotech sector to optimize operations and achieve profitability.

Comparison to Industry Standards

• Ginkgo's revenue growth, while significant due to a non-cash item, is mixed when compared to other synthetic biology companies. Companies like Amyris have faced challenges in achieving consistent revenue growth and profitability.
• The company's focus on large enterprise customers is similar to other companies in the space, such as Zymergen (now acquired by Ginkgo), which also targeted large-scale partnerships.
• Ginkgo's Adjusted EBITDA improvement is a positive sign, but the company still needs to demonstrate consistent profitability, which is a common challenge for many biotech startups.
• The company's biosecurity segment is unique, and its performance is difficult to compare directly to other companies, as it is a relatively new and evolving market.
• The cost-cutting measures and site consolidation are similar to actions taken by other biotech companies facing financial pressures, such as those seen in the broader tech sector.

Management Changes

Related Party Transactions

• Octant, where Dr. Sri Kosuri is CEO and Jason Kelly is on the board, is a commercial partner of Ginkgo, and Ginkgo expects to receive approximately $330,000 in revenue from Octant during the 2024 fiscal year.

Stakeholder Impact

• Shareholders may be concerned about the underlying revenue decline and continued losses, but encouraged by the cost-cutting measures and new partnerships.
• Employees may be affected by the reduction in force and site consolidation.
• Customers may benefit from the company's expanded offerings and partnerships.
• Suppliers may be impacted by the company's cost reduction efforts.
• Creditors may be monitoring the company's progress towards profitability.

Next Steps

• Ginkgo will continue to implement its restructuring plan, including site consolidation and cost reductions.
• The company will focus on expanding its partnerships and delivering on existing contracts.
• Ginkgo will work towards achieving Adjusted EBITDA breakeven by the end of 2026.
• The company will continue to develop and expand its offerings in cell engineering and biosecurity.
• Ginkgo will host a videoconference to discuss the results and outlook.

Key Dates

Keywords

synthetic biology, cell programming, biosecurity, revenue, EBITDA, restructuring, cost reduction, partnerships, Novo Nordisk, Merck, site consolidation, reduction in force, financial results